Articles By Anuja Singh
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
By
Is Merck’s WINREVAIR Set to Redefine First-Year PAH Treatment? Phase 3 HYPERION Results Show…
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP, Redefine Frontline Standards in Transplant-Eligible Multiple…
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results…
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology…
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Is Merck’s WINREVAIR Set to Redefine First-Year PAH Treatment? Phase 3 HYPERION Results Show…
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP, Redefine Frontline Standards in Transplant-Eligible Multiple…
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results…
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology…
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…